nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydroxyurea—head and neck cancer—thyroid cancer	0.821	1	CtDrD
Hydroxyurea—RRM1—larynx—thyroid cancer	0.0119	0.578	CbGeAlD
Hydroxyurea—RRM1—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.00583	0.183	CbGpPWpGaD
Hydroxyurea—RRM2—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.0048	0.151	CbGpPWpGaD
Hydroxyurea—RRM2—G1/S-Specific Transcription—CDK1—thyroid cancer	0.00255	0.0802	CbGpPWpGaD
Hydroxyurea—RRM2—Afatinib—Vandetanib—thyroid cancer	0.00221	0.534	CbGdCrCtD
Hydroxyurea—Mucosal inflammation—Vandetanib—thyroid cancer	0.00215	0.0176	CcSEcCtD
Hydroxyurea—Platelet count decreased—Vandetanib—thyroid cancer	0.00201	0.0163	CcSEcCtD
Hydroxyurea—RRM2—Gefitinib—Vandetanib—thyroid cancer	0.00194	0.466	CbGdCrCtD
Hydroxyurea—RRM1—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00188	0.0592	CbGpPWpGaD
Hydroxyurea—Hypomagnesaemia—Vandetanib—thyroid cancer	0.00188	0.0153	CcSEcCtD
Hydroxyurea—Ureteric obstruction—Epirubicin—thyroid cancer	0.00181	0.0148	CcSEcCtD
Hydroxyurea—RRM2—thyroid gland—thyroid cancer	0.00181	0.0878	CbGeAlD
Hydroxyurea—Urine output—Epirubicin—thyroid cancer	0.00171	0.014	CcSEcCtD
Hydroxyurea—Recall phenomenon—Epirubicin—thyroid cancer	0.00171	0.014	CcSEcCtD
Hydroxyurea—Ureteric obstruction—Doxorubicin—thyroid cancer	0.00168	0.0137	CcSEcCtD
Hydroxyurea—RRM2—head—thyroid cancer	0.00161	0.0779	CbGeAlD
Hydroxyurea—Urine output—Doxorubicin—thyroid cancer	0.00159	0.0129	CcSEcCtD
Hydroxyurea—Recall phenomenon—Doxorubicin—thyroid cancer	0.00159	0.0129	CcSEcCtD
Hydroxyurea—Metastatic neoplasm—Epirubicin—thyroid cancer	0.00155	0.0126	CcSEcCtD
Hydroxyurea—RRM2—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00155	0.0488	CbGpPWpGaD
Hydroxyurea—Skin ulcer—Vandetanib—thyroid cancer	0.00153	0.0125	CcSEcCtD
Hydroxyurea—RRM1—thyroid gland—thyroid cancer	0.0015	0.0729	CbGeAlD
Hydroxyurea—RRM2—E2F mediated regulation of DNA replication—CDK1—thyroid cancer	0.0015	0.0472	CbGpPWpGaD
Hydroxyurea—Mucosal inflammation—Sorafenib—thyroid cancer	0.00145	0.0118	CcSEcCtD
Hydroxyurea—Metastatic neoplasm—Doxorubicin—thyroid cancer	0.00144	0.0117	CcSEcCtD
Hydroxyurea—Oligospermia—Epirubicin—thyroid cancer	0.00142	0.0116	CcSEcCtD
Hydroxyurea—Gastrointestinal symptom NOS—Sorafenib—thyroid cancer	0.00137	0.0111	CcSEcCtD
Hydroxyurea—RRM1—head—thyroid cancer	0.00133	0.0647	CbGeAlD
Hydroxyurea—Oligospermia—Doxorubicin—thyroid cancer	0.00131	0.0107	CcSEcCtD
Hydroxyurea—Creatinine increased—Vandetanib—thyroid cancer	0.00125	0.0102	CcSEcCtD
Hydroxyurea—RRM2—lymph node—thyroid cancer	0.00113	0.0545	CbGeAlD
Hydroxyurea—Azoospermia—Epirubicin—thyroid cancer	0.0011	0.009	CcSEcCtD
Hydroxyurea—Leukaemia—Epirubicin—thyroid cancer	0.0011	0.009	CcSEcCtD
Hydroxyurea—Neoplasm—Vandetanib—thyroid cancer	0.00108	0.00879	CcSEcCtD
Hydroxyurea—Leukaemia—Doxorubicin—thyroid cancer	0.00102	0.00832	CcSEcCtD
Hydroxyurea—Azoospermia—Doxorubicin—thyroid cancer	0.00102	0.00832	CcSEcCtD
Hydroxyurea—RRM1—E2F transcription factor network—CDK1—thyroid cancer	0.000966	0.0304	CbGpPWpGaD
Hydroxyurea—RRM1—lymph node—thyroid cancer	0.000935	0.0453	CbGeAlD
Hydroxyurea—Dermatitis bullous—Vandetanib—thyroid cancer	0.000906	0.00738	CcSEcCtD
Hydroxyurea—Skin necrosis—Epirubicin—thyroid cancer	0.000851	0.00693	CcSEcCtD
Hydroxyurea—RRM1—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.000839	0.0264	CbGpPWpGaD
Hydroxyurea—Blood creatinine increased—Vandetanib—thyroid cancer	0.000811	0.00661	CcSEcCtD
Hydroxyurea—RRM2—E2F transcription factor network—CDK1—thyroid cancer	0.000795	0.025	CbGpPWpGaD
Hydroxyurea—Skin necrosis—Doxorubicin—thyroid cancer	0.000788	0.00642	CcSEcCtD
Hydroxyurea—Skin exfoliation—Sorafenib—thyroid cancer	0.000768	0.00626	CcSEcCtD
Hydroxyurea—Pancreatitis—Vandetanib—thyroid cancer	0.000734	0.00598	CcSEcCtD
Hydroxyurea—Neoplasm—Sorafenib—thyroid cancer	0.000728	0.00593	CcSEcCtD
Hydroxyurea—Neutropenia—Vandetanib—thyroid cancer	0.0007	0.0057	CcSEcCtD
Hydroxyurea—Dysuria—Vandetanib—thyroid cancer	0.0007	0.0057	CcSEcCtD
Hydroxyurea—RRM2—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.000691	0.0217	CbGpPWpGaD
Hydroxyurea—Infestation—Vandetanib—thyroid cancer	0.000667	0.00544	CcSEcCtD
Hydroxyurea—Infestation NOS—Vandetanib—thyroid cancer	0.000667	0.00544	CcSEcCtD
Hydroxyurea—Stomatitis—Vandetanib—thyroid cancer	0.000651	0.0053	CcSEcCtD
Hydroxyurea—Hepatic failure—Sorafenib—thyroid cancer	0.00065	0.0053	CcSEcCtD
Hydroxyurea—Myelosuppression—Epirubicin—thyroid cancer	0.000634	0.00517	CcSEcCtD
Hydroxyurea—Renal failure acute—Sorafenib—thyroid cancer	0.000633	0.00515	CcSEcCtD
Hydroxyurea—Hepatobiliary disease—Vandetanib—thyroid cancer	0.000631	0.00514	CcSEcCtD
Hydroxyurea—Haemoglobin—Vandetanib—thyroid cancer	0.000602	0.0049	CcSEcCtD
Hydroxyurea—Haemorrhage—Vandetanib—thyroid cancer	0.000599	0.00488	CcSEcCtD
Hydroxyurea—Myelosuppression—Doxorubicin—thyroid cancer	0.000587	0.00478	CcSEcCtD
Hydroxyurea—RRM2—G1/S Transition—CDK1—thyroid cancer	0.000577	0.0181	CbGpPWpGaD
Hydroxyurea—Angiopathy—Vandetanib—thyroid cancer	0.000544	0.00443	CcSEcCtD
Hydroxyurea—Mucosal inflammation—Epirubicin—thyroid cancer	0.000537	0.00438	CcSEcCtD
Hydroxyurea—Alopecia—Vandetanib—thyroid cancer	0.000529	0.00431	CcSEcCtD
Hydroxyurea—Breast disorder—Sorafenib—thyroid cancer	0.000528	0.0043	CcSEcCtD
Hydroxyurea—Skin hyperpigmentation—Epirubicin—thyroid cancer	0.0005	0.00407	CcSEcCtD
Hydroxyurea—RRM1—Fluoropyrimidine Activity—TP53—thyroid cancer	0.0005	0.0157	CbGpPWpGaD
Hydroxyurea—Mucosal inflammation—Doxorubicin—thyroid cancer	0.000497	0.00405	CcSEcCtD
Hydroxyurea—Pancreatitis—Sorafenib—thyroid cancer	0.000495	0.00403	CcSEcCtD
Hydroxyurea—Febrile neutropenia—Epirubicin—thyroid cancer	0.000494	0.00403	CcSEcCtD
Hydroxyurea—RRM2—Mitotic G1-G1/S phases—CDK1—thyroid cancer	0.000486	0.0153	CbGpPWpGaD
Hydroxyurea—Eruption—Epirubicin—thyroid cancer	0.000484	0.00394	CcSEcCtD
Hydroxyurea—Neutropenia—Sorafenib—thyroid cancer	0.000472	0.00385	CcSEcCtD
Hydroxyurea—Hypomagnesaemia—Epirubicin—thyroid cancer	0.000468	0.00381	CcSEcCtD
Hydroxyurea—Skin hyperpigmentation—Doxorubicin—thyroid cancer	0.000463	0.00377	CcSEcCtD
Hydroxyurea—Febrile neutropenia—Doxorubicin—thyroid cancer	0.000457	0.00373	CcSEcCtD
Hydroxyurea—Convulsion—Vandetanib—thyroid cancer	0.000452	0.00368	CcSEcCtD
Hydroxyurea—Infestation NOS—Sorafenib—thyroid cancer	0.00045	0.00367	CcSEcCtD
Hydroxyurea—Infestation—Sorafenib—thyroid cancer	0.00045	0.00367	CcSEcCtD
Hydroxyurea—Eruption—Doxorubicin—thyroid cancer	0.000447	0.00364	CcSEcCtD
Hydroxyurea—Neuropathy peripheral—Sorafenib—thyroid cancer	0.000441	0.00359	CcSEcCtD
Hydroxyurea—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.000441	0.00359	CcSEcCtD
Hydroxyurea—Bone marrow depression—Epirubicin—thyroid cancer	0.000441	0.00359	CcSEcCtD
Hydroxyurea—Stomatitis—Sorafenib—thyroid cancer	0.000439	0.00357	CcSEcCtD
Hydroxyurea—Hypomagnesaemia—Doxorubicin—thyroid cancer	0.000433	0.00353	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.000431	0.0135	CbGpPWpGaD
Hydroxyurea—Hepatobiliary disease—Sorafenib—thyroid cancer	0.000426	0.00347	CcSEcCtD
Hydroxyurea—Oedema—Vandetanib—thyroid cancer	0.000426	0.00347	CcSEcCtD
Hydroxyurea—Infection—Vandetanib—thyroid cancer	0.000423	0.00344	CcSEcCtD
Hydroxyurea—Nervous system disorder—Vandetanib—thyroid cancer	0.000417	0.0034	CcSEcCtD
Hydroxyurea—Thrombocytopenia—Vandetanib—thyroid cancer	0.000417	0.00339	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000415	0.0131	CbGpPWpGaD
Hydroxyurea—Skin disorder—Vandetanib—thyroid cancer	0.000413	0.00337	CcSEcCtD
Hydroxyurea—Blister—Epirubicin—thyroid cancer	0.000413	0.00336	CcSEcCtD
Hydroxyurea—RRM2—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000412	0.0129	CbGpPWpGaD
Hydroxyurea—Bone marrow depression—Doxorubicin—thyroid cancer	0.000408	0.00332	CcSEcCtD
Hydroxyurea—Haemoglobin—Sorafenib—thyroid cancer	0.000406	0.00331	CcSEcCtD
Hydroxyurea—Haemorrhage—Sorafenib—thyroid cancer	0.000404	0.00329	CcSEcCtD
Hydroxyurea—CYP2D6—head—thyroid cancer	0.000397	0.0192	CbGeAlD
Hydroxyurea—RRM2—Cell Cycle—PCM1—thyroid cancer	0.000385	0.0121	CbGpPWpGaD
Hydroxyurea—Skin ulcer—Epirubicin—thyroid cancer	0.000382	0.00311	CcSEcCtD
Hydroxyurea—Blister—Doxorubicin—thyroid cancer	0.000382	0.00311	CcSEcCtD
Hydroxyurea—Dyspnoea—Vandetanib—thyroid cancer	0.000379	0.00309	CcSEcCtD
Hydroxyurea—Dyspepsia—Vandetanib—thyroid cancer	0.000375	0.00305	CcSEcCtD
Hydroxyurea—Decreased appetite—Vandetanib—thyroid cancer	0.00037	0.00301	CcSEcCtD
Hydroxyurea—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000367	0.00299	CcSEcCtD
Hydroxyurea—Fatigue—Vandetanib—thyroid cancer	0.000367	0.00299	CcSEcCtD
Hydroxyurea—Angiopathy—Sorafenib—thyroid cancer	0.000367	0.00299	CcSEcCtD
Hydroxyurea—Constipation—Vandetanib—thyroid cancer	0.000364	0.00296	CcSEcCtD
Hydroxyurea—Pain—Vandetanib—thyroid cancer	0.000364	0.00296	CcSEcCtD
Hydroxyurea—Alopecia—Sorafenib—thyroid cancer	0.000357	0.00291	CcSEcCtD
Hydroxyurea—Skin ulcer—Doxorubicin—thyroid cancer	0.000354	0.00288	CcSEcCtD
Hydroxyurea—Erythema—Sorafenib—thyroid cancer	0.000352	0.00287	CcSEcCtD
Hydroxyurea—RRM1—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.00035	0.011	CbGpPWpGaD
Hydroxyurea—Amenorrhoea—Epirubicin—thyroid cancer	0.000339	0.00276	CcSEcCtD
Hydroxyurea—Body temperature increased—Vandetanib—thyroid cancer	0.000336	0.00274	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—MINPP1—thyroid cancer	0.000332	0.0104	CbGpPWpGaD
Hydroxyurea—Anaemia—Sorafenib—thyroid cancer	0.000325	0.00265	CcSEcCtD
Hydroxyurea—Hyperuricaemia—Epirubicin—thyroid cancer	0.000321	0.00261	CcSEcCtD
Hydroxyurea—Leukopenia—Sorafenib—thyroid cancer	0.000315	0.00257	CcSEcCtD
Hydroxyurea—Ulcer—Epirubicin—thyroid cancer	0.000314	0.00256	CcSEcCtD
Hydroxyurea—Amenorrhoea—Doxorubicin—thyroid cancer	0.000313	0.00255	CcSEcCtD
Hydroxyurea—Creatinine increased—Epirubicin—thyroid cancer	0.000312	0.00255	CcSEcCtD
Hydroxyurea—Asthenia—Vandetanib—thyroid cancer	0.000305	0.00249	CcSEcCtD
Hydroxyurea—Blood uric acid increased—Epirubicin—thyroid cancer	0.000303	0.00247	CcSEcCtD
Hydroxyurea—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000297	0.00242	CcSEcCtD
Hydroxyurea—Hyperuricaemia—Doxorubicin—thyroid cancer	0.000297	0.00242	CcSEcCtD
Hydroxyurea—Diarrhoea—Vandetanib—thyroid cancer	0.000291	0.00237	CcSEcCtD
Hydroxyurea—Ulcer—Doxorubicin—thyroid cancer	0.000291	0.00237	CcSEcCtD
Hydroxyurea—Creatinine increased—Doxorubicin—thyroid cancer	0.000289	0.00235	CcSEcCtD
Hydroxyurea—RRM2—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000288	0.00905	CbGpPWpGaD
Hydroxyurea—Infection—Sorafenib—thyroid cancer	0.000285	0.00232	CcSEcCtD
Hydroxyurea—Skin exfoliation—Epirubicin—thyroid cancer	0.000284	0.00231	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—NDUFA13—thyroid cancer	0.000282	0.00887	CbGpPWpGaD
Hydroxyurea—Nervous system disorder—Sorafenib—thyroid cancer	0.000282	0.00229	CcSEcCtD
Hydroxyurea—Dizziness—Vandetanib—thyroid cancer	0.000281	0.00229	CcSEcCtD
Hydroxyurea—Thrombocytopenia—Sorafenib—thyroid cancer	0.000281	0.00229	CcSEcCtD
Hydroxyurea—Blood urea increased—Epirubicin—thyroid cancer	0.000281	0.00229	CcSEcCtD
Hydroxyurea—Blood uric acid increased—Doxorubicin—thyroid cancer	0.00028	0.00228	CcSEcCtD
Hydroxyurea—Skin disorder—Sorafenib—thyroid cancer	0.000279	0.00227	CcSEcCtD
Hydroxyurea—Anorexia—Sorafenib—thyroid cancer	0.000274	0.00223	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—MINPP1—thyroid cancer	0.000273	0.00859	CbGpPWpGaD
Hydroxyurea—Vomiting—Vandetanib—thyroid cancer	0.000271	0.0022	CcSEcCtD
Hydroxyurea—Rash maculo-papular—Epirubicin—thyroid cancer	0.00027	0.0022	CcSEcCtD
Hydroxyurea—Neoplasm—Epirubicin—thyroid cancer	0.000269	0.00219	CcSEcCtD
Hydroxyurea—Rash—Vandetanib—thyroid cancer	0.000268	0.00219	CcSEcCtD
Hydroxyurea—Dermatitis—Vandetanib—thyroid cancer	0.000268	0.00218	CcSEcCtD
Hydroxyurea—Headache—Vandetanib—thyroid cancer	0.000267	0.00217	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—CHST14—thyroid cancer	0.000265	0.00834	CbGpPWpGaD
Hydroxyurea—Pulmonary oedema—Epirubicin—thyroid cancer	0.000265	0.00216	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—TPR—thyroid cancer	0.000263	0.00828	CbGpPWpGaD
Hydroxyurea—Skin exfoliation—Doxorubicin—thyroid cancer	0.000263	0.00214	CcSEcCtD
Hydroxyurea—Blood urea increased—Doxorubicin—thyroid cancer	0.00026	0.00212	CcSEcCtD
Hydroxyurea—Dyspnoea—Sorafenib—thyroid cancer	0.000256	0.00209	CcSEcCtD
Hydroxyurea—Nausea—Vandetanib—thyroid cancer	0.000253	0.00206	CcSEcCtD
Hydroxyurea—Dyspepsia—Sorafenib—thyroid cancer	0.000253	0.00206	CcSEcCtD
Hydroxyurea—Rash maculo-papular—Doxorubicin—thyroid cancer	0.00025	0.00204	CcSEcCtD
Hydroxyurea—Decreased appetite—Sorafenib—thyroid cancer	0.00025	0.00203	CcSEcCtD
Hydroxyurea—Neoplasm—Doxorubicin—thyroid cancer	0.000249	0.00203	CcSEcCtD
Hydroxyurea—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000248	0.00202	CcSEcCtD
Hydroxyurea—Fatigue—Sorafenib—thyroid cancer	0.000248	0.00202	CcSEcCtD
Hydroxyurea—Pain—Sorafenib—thyroid cancer	0.000246	0.002	CcSEcCtD
Hydroxyurea—Constipation—Sorafenib—thyroid cancer	0.000246	0.002	CcSEcCtD
Hydroxyurea—Pulmonary oedema—Doxorubicin—thyroid cancer	0.000245	0.002	CcSEcCtD
Hydroxyurea—Hepatic failure—Epirubicin—thyroid cancer	0.00024	0.00196	CcSEcCtD
Hydroxyurea—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	0.00024	0.00754	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle—TPR—thyroid cancer	0.000235	0.0074	CbGpPWpGaD
Hydroxyurea—Renal failure acute—Epirubicin—thyroid cancer	0.000234	0.0019	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—NDUFA13—thyroid cancer	0.000232	0.0073	CbGpPWpGaD
Hydroxyurea—RRM1—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.00023	0.00724	CbGpPWpGaD
Hydroxyurea—Body temperature increased—Sorafenib—thyroid cancer	0.000227	0.00185	CcSEcCtD
Hydroxyurea—Dermatitis bullous—Epirubicin—thyroid cancer	0.000226	0.00184	CcSEcCtD
Hydroxyurea—Hepatic failure—Doxorubicin—thyroid cancer	0.000222	0.00181	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—CHST14—thyroid cancer	0.000218	0.00687	CbGpPWpGaD
Hydroxyurea—Renal failure acute—Doxorubicin—thyroid cancer	0.000216	0.00176	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—HPGD—thyroid cancer	0.000214	0.00672	CbGpPWpGaD
Hydroxyurea—Hypersensitivity—Sorafenib—thyroid cancer	0.000212	0.00172	CcSEcCtD
Hydroxyurea—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000209	0.0017	CcSEcCtD
Hydroxyurea—Face oedema—Epirubicin—thyroid cancer	0.000208	0.0017	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000206	0.00648	CbGpPWpGaD
Hydroxyurea—Asthenia—Sorafenib—thyroid cancer	0.000206	0.00168	CcSEcCtD
Hydroxyurea—RRM2—Mitotic G1-G1/S phases—CCND1—thyroid cancer	0.000203	0.00637	CbGpPWpGaD
Hydroxyurea—Blood creatinine increased—Epirubicin—thyroid cancer	0.000202	0.00165	CcSEcCtD
Hydroxyurea—Diarrhoea—Sorafenib—thyroid cancer	0.000196	0.0016	CcSEcCtD
Hydroxyurea—Breast disorder—Epirubicin—thyroid cancer	0.000195	0.00159	CcSEcCtD
Hydroxyurea—Face oedema—Doxorubicin—thyroid cancer	0.000193	0.00157	CcSEcCtD
Hydroxyurea—Dizziness—Sorafenib—thyroid cancer	0.00019	0.00155	CcSEcCtD
Hydroxyurea—RRM2—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.00019	0.00596	CbGpPWpGaD
Hydroxyurea—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000187	0.00152	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000186	0.00586	CbGpPWpGaD
Hydroxyurea—Pancreatitis—Epirubicin—thyroid cancer	0.000183	0.00149	CcSEcCtD
Hydroxyurea—Vomiting—Sorafenib—thyroid cancer	0.000183	0.00149	CcSEcCtD
Hydroxyurea—Rash—Sorafenib—thyroid cancer	0.000181	0.00147	CcSEcCtD
Hydroxyurea—Dermatitis—Sorafenib—thyroid cancer	0.000181	0.00147	CcSEcCtD
Hydroxyurea—Breast disorder—Doxorubicin—thyroid cancer	0.000181	0.00147	CcSEcCtD
Hydroxyurea—Headache—Sorafenib—thyroid cancer	0.00018	0.00147	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.00018	0.00566	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.000178	0.00561	CbGpPWpGaD
Hydroxyurea—Pancytopenia—Epirubicin—thyroid cancer	0.000177	0.00144	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—HPGD—thyroid cancer	0.000176	0.00553	CbGpPWpGaD
Hydroxyurea—Neutropenia—Epirubicin—thyroid cancer	0.000174	0.00142	CcSEcCtD
Hydroxyurea—Dysuria—Epirubicin—thyroid cancer	0.000174	0.00142	CcSEcCtD
Hydroxyurea—Nausea—Sorafenib—thyroid cancer	0.000171	0.00139	CcSEcCtD
Hydroxyurea—Weight increased—Epirubicin—thyroid cancer	0.00017	0.00138	CcSEcCtD
Hydroxyurea—Pancreatitis—Doxorubicin—thyroid cancer	0.000169	0.00138	CcSEcCtD
Hydroxyurea—Infestation—Epirubicin—thyroid cancer	0.000166	0.00136	CcSEcCtD
Hydroxyurea—Drowsiness—Epirubicin—thyroid cancer	0.000166	0.00136	CcSEcCtD
Hydroxyurea—Infestation NOS—Epirubicin—thyroid cancer	0.000166	0.00136	CcSEcCtD
Hydroxyurea—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000165	0.00517	CbGpPWpGaD
Hydroxyurea—Pancytopenia—Doxorubicin—thyroid cancer	0.000164	0.00134	CcSEcCtD
Hydroxyurea—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000163	0.00133	CcSEcCtD
Hydroxyurea—Stomatitis—Epirubicin—thyroid cancer	0.000162	0.00132	CcSEcCtD
Hydroxyurea—Dysuria—Doxorubicin—thyroid cancer	0.000161	0.00132	CcSEcCtD
Hydroxyurea—Neutropenia—Doxorubicin—thyroid cancer	0.000161	0.00132	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—CDK1—thyroid cancer	0.000159	0.00501	CbGpPWpGaD
Hydroxyurea—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000157	0.00128	CcSEcCtD
Hydroxyurea—Weight increased—Doxorubicin—thyroid cancer	0.000157	0.00128	CcSEcCtD
Hydroxyurea—Infestation NOS—Doxorubicin—thyroid cancer	0.000154	0.00125	CcSEcCtD
Hydroxyurea—Infestation—Doxorubicin—thyroid cancer	0.000154	0.00125	CcSEcCtD
Hydroxyurea—Drowsiness—Doxorubicin—thyroid cancer	0.000154	0.00125	CcSEcCtD
Hydroxyurea—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000151	0.00123	CcSEcCtD
Hydroxyurea—Haemoglobin—Epirubicin—thyroid cancer	0.00015	0.00122	CcSEcCtD
Hydroxyurea—Stomatitis—Doxorubicin—thyroid cancer	0.00015	0.00122	CcSEcCtD
Hydroxyurea—Haemorrhage—Epirubicin—thyroid cancer	0.000149	0.00122	CcSEcCtD
Hydroxyurea—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000146	0.00119	CcSEcCtD
Hydroxyurea—Haemoglobin—Doxorubicin—thyroid cancer	0.000139	0.00113	CcSEcCtD
Hydroxyurea—Haemorrhage—Doxorubicin—thyroid cancer	0.000138	0.00113	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000138	0.00434	CbGpPWpGaD
Hydroxyurea—Angiopathy—Epirubicin—thyroid cancer	0.000136	0.0011	CcSEcCtD
Hydroxyurea—Chills—Epirubicin—thyroid cancer	0.000134	0.00109	CcSEcCtD
Hydroxyurea—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000133	0.00419	CbGpPWpGaD
Hydroxyurea—Alopecia—Epirubicin—thyroid cancer	0.000132	0.00108	CcSEcCtD
Hydroxyurea—Erythema—Epirubicin—thyroid cancer	0.00013	0.00106	CcSEcCtD
Hydroxyurea—Angiopathy—Doxorubicin—thyroid cancer	0.000125	0.00102	CcSEcCtD
Hydroxyurea—Chills—Doxorubicin—thyroid cancer	0.000124	0.00101	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—TPR—thyroid cancer	0.000123	0.00386	CbGpPWpGaD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000123	0.00386	CbGpPWpGaD
Hydroxyurea—Alopecia—Doxorubicin—thyroid cancer	0.000122	0.000995	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—PRKAR1A—thyroid cancer	0.000121	0.0038	CbGpPWpGaD
Hydroxyurea—Ill-defined disorder—Epirubicin—thyroid cancer	0.000121	0.000983	CcSEcCtD
Hydroxyurea—Erythema—Doxorubicin—thyroid cancer	0.00012	0.00098	CcSEcCtD
Hydroxyurea—Anaemia—Epirubicin—thyroid cancer	0.00012	0.000979	CcSEcCtD
Hydroxyurea—Malaise—Epirubicin—thyroid cancer	0.000117	0.000955	CcSEcCtD
Hydroxyurea—Leukopenia—Epirubicin—thyroid cancer	0.000116	0.000948	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—TERT—thyroid cancer	0.000115	0.00361	CbGpPWpGaD
Hydroxyurea—Convulsion—Epirubicin—thyroid cancer	0.000113	0.000918	CcSEcCtD
Hydroxyurea—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000112	0.000909	CcSEcCtD
Hydroxyurea—Anaemia—Doxorubicin—thyroid cancer	0.000111	0.000906	CcSEcCtD
Hydroxyurea—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00011	0.000895	CcSEcCtD
Hydroxyurea—Discomfort—Epirubicin—thyroid cancer	0.000109	0.000891	CcSEcCtD
Hydroxyurea—Malaise—Doxorubicin—thyroid cancer	0.000108	0.000884	CcSEcCtD
Hydroxyurea—Leukopenia—Doxorubicin—thyroid cancer	0.000108	0.000877	CcSEcCtD
Hydroxyurea—Oedema—Epirubicin—thyroid cancer	0.000106	0.000864	CcSEcCtD
Hydroxyurea—Infection—Epirubicin—thyroid cancer	0.000105	0.000859	CcSEcCtD
Hydroxyurea—Convulsion—Doxorubicin—thyroid cancer	0.000104	0.000849	CcSEcCtD
Hydroxyurea—Nervous system disorder—Epirubicin—thyroid cancer	0.000104	0.000848	CcSEcCtD
Hydroxyurea—Thrombocytopenia—Epirubicin—thyroid cancer	0.000104	0.000846	CcSEcCtD
Hydroxyurea—RRM1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000104	0.00326	CbGpPWpGaD
Hydroxyurea—Skin disorder—Epirubicin—thyroid cancer	0.000103	0.00084	CcSEcCtD
Hydroxyurea—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000102	0.000829	CcSEcCtD
Hydroxyurea—Discomfort—Doxorubicin—thyroid cancer	0.000101	0.000824	CcSEcCtD
Hydroxyurea—Anorexia—Epirubicin—thyroid cancer	0.000101	0.000824	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—TPR—thyroid cancer	0.000101	0.00318	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—PRKAR1A—thyroid cancer	9.95e-05	0.00313	CbGpPWpGaD
Hydroxyurea—Oedema—Doxorubicin—thyroid cancer	9.82e-05	0.0008	CcSEcCtD
Hydroxyurea—Infection—Doxorubicin—thyroid cancer	9.75e-05	0.000795	CcSEcCtD
Hydroxyurea—Nervous system disorder—Doxorubicin—thyroid cancer	9.63e-05	0.000784	CcSEcCtD
Hydroxyurea—Thrombocytopenia—Doxorubicin—thyroid cancer	9.61e-05	0.000783	CcSEcCtD
Hydroxyurea—Skin disorder—Doxorubicin—thyroid cancer	9.54e-05	0.000777	CcSEcCtD
Hydroxyurea—Dyspnoea—Epirubicin—thyroid cancer	9.46e-05	0.000771	CcSEcCtD
Hydroxyurea—Somnolence—Epirubicin—thyroid cancer	9.43e-05	0.000768	CcSEcCtD
Hydroxyurea—Anorexia—Doxorubicin—thyroid cancer	9.36e-05	0.000762	CcSEcCtD
Hydroxyurea—Dyspepsia—Epirubicin—thyroid cancer	9.34e-05	0.000761	CcSEcCtD
Hydroxyurea—Decreased appetite—Epirubicin—thyroid cancer	9.22e-05	0.000751	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—SLC5A5—thyroid cancer	9.19e-05	0.00289	CbGpPWpGaD
Hydroxyurea—Gastrointestinal disorder—Epirubicin—thyroid cancer	9.16e-05	0.000746	CcSEcCtD
Hydroxyurea—Fatigue—Epirubicin—thyroid cancer	9.15e-05	0.000745	CcSEcCtD
Hydroxyurea—Pain—Epirubicin—thyroid cancer	9.07e-05	0.000739	CcSEcCtD
Hydroxyurea—Constipation—Epirubicin—thyroid cancer	9.07e-05	0.000739	CcSEcCtD
Hydroxyurea—Dyspnoea—Doxorubicin—thyroid cancer	8.75e-05	0.000713	CcSEcCtD
Hydroxyurea—Feeling abnormal—Epirubicin—thyroid cancer	8.74e-05	0.000712	CcSEcCtD
Hydroxyurea—Somnolence—Doxorubicin—thyroid cancer	8.73e-05	0.000711	CcSEcCtD
Hydroxyurea—Dyspepsia—Doxorubicin—thyroid cancer	8.64e-05	0.000704	CcSEcCtD
Hydroxyurea—Decreased appetite—Doxorubicin—thyroid cancer	8.54e-05	0.000695	CcSEcCtD
Hydroxyurea—Gastrointestinal disorder—Doxorubicin—thyroid cancer	8.48e-05	0.00069	CcSEcCtD
Hydroxyurea—Fatigue—Doxorubicin—thyroid cancer	8.47e-05	0.00069	CcSEcCtD
Hydroxyurea—Pain—Doxorubicin—thyroid cancer	8.4e-05	0.000684	CcSEcCtD
Hydroxyurea—Constipation—Doxorubicin—thyroid cancer	8.4e-05	0.000684	CcSEcCtD
Hydroxyurea—Body temperature increased—Epirubicin—thyroid cancer	8.39e-05	0.000683	CcSEcCtD
Hydroxyurea—Feeling abnormal—Doxorubicin—thyroid cancer	8.09e-05	0.000659	CcSEcCtD
Hydroxyurea—Hypersensitivity—Epirubicin—thyroid cancer	7.82e-05	0.000637	CcSEcCtD
Hydroxyurea—Body temperature increased—Doxorubicin—thyroid cancer	7.76e-05	0.000632	CcSEcCtD
Hydroxyurea—RRM1—Metabolism—RXRA—thyroid cancer	7.72e-05	0.00243	CbGpPWpGaD
Hydroxyurea—Asthenia—Epirubicin—thyroid cancer	7.61e-05	0.00062	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—SLC5A5—thyroid cancer	7.57e-05	0.00238	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle, Mitotic—CCND1—thyroid cancer	7.43e-05	0.00234	CbGpPWpGaD
Hydroxyurea—Diarrhoea—Epirubicin—thyroid cancer	7.26e-05	0.000591	CcSEcCtD
Hydroxyurea—Hypersensitivity—Doxorubicin—thyroid cancer	7.23e-05	0.000589	CcSEcCtD
Hydroxyurea—CYP2D6—Biological oxidations—RXRA—thyroid cancer	7.08e-05	0.00223	CbGpPWpGaD
Hydroxyurea—Asthenia—Doxorubicin—thyroid cancer	7.04e-05	0.000574	CcSEcCtD
Hydroxyurea—Dizziness—Epirubicin—thyroid cancer	7.02e-05	0.000572	CcSEcCtD
Hydroxyurea—Vomiting—Epirubicin—thyroid cancer	6.75e-05	0.00055	CcSEcCtD
Hydroxyurea—Diarrhoea—Doxorubicin—thyroid cancer	6.72e-05	0.000547	CcSEcCtD
Hydroxyurea—Rash—Epirubicin—thyroid cancer	6.69e-05	0.000545	CcSEcCtD
Hydroxyurea—Dermatitis—Epirubicin—thyroid cancer	6.68e-05	0.000544	CcSEcCtD
Hydroxyurea—Headache—Epirubicin—thyroid cancer	6.65e-05	0.000541	CcSEcCtD
Hydroxyurea—RRM2—Cell Cycle—CCND1—thyroid cancer	6.64e-05	0.00209	CbGpPWpGaD
Hydroxyurea—Dizziness—Doxorubicin—thyroid cancer	6.49e-05	0.000529	CcSEcCtD
Hydroxyurea—RRM2—Metabolism—RXRA—thyroid cancer	6.36e-05	0.002	CbGpPWpGaD
Hydroxyurea—Nausea—Epirubicin—thyroid cancer	6.3e-05	0.000513	CcSEcCtD
Hydroxyurea—Vomiting—Doxorubicin—thyroid cancer	6.24e-05	0.000508	CcSEcCtD
Hydroxyurea—Rash—Doxorubicin—thyroid cancer	6.19e-05	0.000504	CcSEcCtD
Hydroxyurea—Dermatitis—Doxorubicin—thyroid cancer	6.19e-05	0.000504	CcSEcCtD
Hydroxyurea—Headache—Doxorubicin—thyroid cancer	6.15e-05	0.000501	CcSEcCtD
Hydroxyurea—Nausea—Doxorubicin—thyroid cancer	5.83e-05	0.000475	CcSEcCtD
Hydroxyurea—CYP2D6—Metabolism—MINPP1—thyroid cancer	5.2e-05	0.00164	CbGpPWpGaD
Hydroxyurea—RRM1—Metabolism—PPARG—thyroid cancer	4.88e-05	0.00153	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—NDUFA13—thyroid cancer	4.43e-05	0.00139	CbGpPWpGaD
Hydroxyurea—RRM2—Cell Cycle—TP53—thyroid cancer	4.38e-05	0.00138	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—CHST14—thyroid cancer	4.16e-05	0.00131	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—PPARG—thyroid cancer	4.01e-05	0.00126	CbGpPWpGaD
Hydroxyurea—RRM1—Metabolism—PTGS2—thyroid cancer	3.84e-05	0.00121	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—HPGD—thyroid cancer	3.35e-05	0.00105	CbGpPWpGaD
Hydroxyurea—RRM1—Metabolism—PTEN—thyroid cancer	3.34e-05	0.00105	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—PTGS2—thyroid cancer	3.16e-05	0.000993	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—PTEN—thyroid cancer	2.75e-05	0.000866	CbGpPWpGaD
Hydroxyurea—RRM1—Metabolism—AKT1—thyroid cancer	1.93e-05	0.000606	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—TPR—thyroid cancer	1.93e-05	0.000606	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.9e-05	0.000596	CbGpPWpGaD
Hydroxyurea—RRM2—Metabolism—AKT1—thyroid cancer	1.59e-05	0.000499	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.44e-05	0.000453	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—RXRA—thyroid cancer	1.21e-05	0.000381	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—PPARG—thyroid cancer	7.65e-06	0.000241	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—PTGS2—thyroid cancer	6.02e-06	0.000189	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—PTEN—thyroid cancer	5.25e-06	0.000165	CbGpPWpGaD
Hydroxyurea—CYP2D6—Metabolism—AKT1—thyroid cancer	3.02e-06	9.51e-05	CbGpPWpGaD
